Literature DB >> 24527766

Imploding and exploding migraine headaches: comparison of methods to diagnose pain directionality.

Julia A Files1, Todd J Schwedt, Anita P Mayer, Paru S David, Bert B Vargas, Yu-Hui Chang, Megan Hunt, Salma Patel, Marcia G Ko, Beverly S Tozer, Rami Burstein, David W Dodick.   

Abstract

BACKGROUND: The study aims to compare methods of determining headache directionality (imploding, exploding, and/or ocular headaches) in women with migraine, investigate the concordance between physician assignment and patient self-assignment of pain directionality, and evaluate whether patients assigned their headaches to the same direction when queried using different methods. Directionality of migraine headache pain (imploding, exploding, or ocular) may reflect differences in the underlying pathogenesis of individual migraine attacks among and within individuals. Emerging evidence suggests that directionality of pain in migraine sufferers may predict response to onabotulinumtoxin A. The best method of determining headache directionality in migraine sufferers has not been systematically explored.
METHODS: We conducted a prospective cross-sectional survey study of 198 female patients with migraine presenting to a Women's Health Clinic. Patients determined the directionality (imploding, exploding, and/or ocular) of their own migraine pain by choosing among 3 pictures graphically representing directionality and also by responding to a written question regarding directionality. Clinicians then classified directionality of migraine pain using structured interviews. Concordance between clinician assignment of directionality and patient self-assignment was determined with Kappa coefficients.
RESULTS: Subjects were females between the ages of 18 and 77 years (mean 48 years). According to patient selection of representative pictures, 62 (31.6%) had imploding headaches with or without ocular pain, 36 (18.4%) had exploding headaches with or without ocular pain, 78 (39.8%) had ocular pain only, and 20 (10.2%) had imploding and exploding headaches with or without ocular pain. Two subjects did not respond. According to patient responses to a written question, 80 (41.0%) had imploding headaches with or without ocular pain, 53 (27.2%) had exploding headaches with or without ocular pain, 46 (23.6%) had ocular pain only, and 16 (8.2%) had imploding and exploding headaches with or without ocular pain. Three subjects did not respond. For physician assignment, 69 (34.9%) subjects had imploding headaches with or without ocular pain, 89 (45%) had exploding headaches with or without ocular pain, 14 (7.1%) had ocular pain only, and 26 (13.1%) had imploding and exploding headaches with or without ocular pain. The concordance (Kappa coefficient) between physician assignment of headache directionality with patient response to the written question was 0.33 (weak agreement), between physician assignment and patient assignment via selection of representative pictures was 0.35 (weak agreement), and between patient assignment via written question and via selection of representative pictures was 0.35 (weak agreement).
CONCLUSIONS: The assignment of headache directionality varied substantially depending upon the method of determination. The concordance between clinician assignment, patient-self assignment via answering a written question, and patient self-assignment via choosing a representative picture was weak. Improved methods of determining pain directionality are needed.
© 2014 American Headache Society.

Entities:  

Keywords:  headache classification; headache directionality; migraine; ocular headache; onabotulinum toxin; pain

Mesh:

Year:  2014        PMID: 24527766      PMCID: PMC4452952          DOI: 10.1111/head.12335

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  12 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

2.  Squeezing life into botulinum toxin A in migraine: imploding versus exploding pain.

Authors:  Peter J Goadsby
Journal:  Pain       Date:  2006-10-25       Impact factor: 6.961

3.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

4.  Migraine prevalence, disease burden, and the need for preventive therapy.

Authors:  R B Lipton; M E Bigal; M Diamond; F Freitag; M L Reed; W F Stewart
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

5.  Predicting migraine responsiveness to botulinum toxin type A injections.

Authors:  Christine C Kim; Megan M Bogart; Sue Ann Wee; Rami Burstein; Kenneth A Arndt; Jeffrey S Dover
Journal:  Arch Dermatol       Date:  2010-02

6.  Sensory innervation of the calvarial bones of the mouse.

Authors:  Bela Kosaras; Moshe Jakubowski; Vanessa Kainz; Rami Burstein
Journal:  J Comp Neurol       Date:  2009-07-20       Impact factor: 3.215

7.  Migraine prophylaxis with botulinum toxin A is associated with perception of headache.

Authors:  Rami Burstein; David Dodick; Stephen Silberstein
Journal:  Toxicon       Date:  2009-01-22       Impact factor: 3.033

8.  Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting.

Authors:  Trevor S Gibbs; Alan B Fleischer; Steven R Feldman; Maria C Sam; Cormac A O'Donovan
Journal:  Headache       Date:  2003-04       Impact factor: 5.887

9.  Scalp periarterial saline efficacy in migraine and relation to exploding and imploding headache.

Authors:  Carlo Cianchetti; Yousef Hmaidan; Gabriele Finco; Maria Giuseppina Ledda
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

10.  Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.

Authors:  Moshe Jakubowski; Peter J McAllister; Zahid H Bajwa; Thomas N Ward; Patty Smith; Rami Burstein
Journal:  Pain       Date:  2006-10-25       Impact factor: 7.926

View more
  1 in total

Review 1.  Extracranial origin of headache.

Authors:  Rami Burstein; Pamela Blake; Aaron Schain; Carlton Perry
Journal:  Curr Opin Neurol       Date:  2017-06       Impact factor: 5.710

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.